Zacks Investment Research Lowers INDIVIOR PLC/S (OTCMKTS:INVVY) to Hold

Share on StockTwits

Zacks Investment Research downgraded shares of INDIVIOR PLC/S (OTCMKTS:INVVY) from a buy rating to a hold rating in a research note issued to investors on Wednesday morning, Zacks.com reports.

According to Zacks, “Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States. “

INVVY stock opened at $2.85 on Wednesday. INDIVIOR PLC/S has a 12-month low of $1.98 and a 12-month high of $7.74. The company has a market cap of $434.07 million, a price-to-earnings ratio of 2.59 and a beta of -0.20. The company has a 50 day moving average of $2.59 and a two-hundred day moving average of $2.95.

INDIVIOR PLC/S (OTCMKTS:INVVY) last released its earnings results on Thursday, February 13th. The company reported ($0.25) earnings per share (EPS) for the quarter. INDIVIOR PLC/S had a return on equity of 132.33% and a net margin of 17.07%. The company had revenue of $133.00 million during the quarter. As a group, analysts expect that INDIVIOR PLC/S will post 0.43 EPS for the current fiscal year.

About INDIVIOR PLC/S

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, opiate overdose, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.

Featured Story: What is the Book Value of a Share?

Get a free copy of the Zacks research report on INDIVIOR PLC/S (INVVY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for INDIVIOR PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INDIVIOR PLC/S and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.